ADMA Biologics, Inc.

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Consensus

—

Average target

$16.00

Implied upside

—

Analysts

—

Why Is ADMA Down Today?

ADMA Biologics is trading down $0.34 (2.89%) today, underperforming the broader market despite limited company-specific catalyst announcements. The stock's decline appears driven by general market headwinds rather than major negative news, though the absence of positive catalysts is also weighing on investor sentiment.

Bottom line: ADMA's 2.89% decline appears driven more by lack of positive momentum and broader biotech sector weakness rather than major negative developments. Investors should remain alert for upcoming clinical or commercial catalysts that could reverse the downtrend, while monitoring the stock's technical support levels.